PayerTalkCE Presents: Myasthenia Gravis (MG): A Managed Care Guide for Emerging Evidence-Based Management Strategies

Learn About:

The clinical features and neuropathology of myasthenia gravis
Recommendations from current myasthenia gravis treatment guidelines
The treatment pipeline and new mechanisms of action
Opportunities to improve patient wellbeing, caregiver burden, access to care, and health inequities

Expert Faculty Presenters


	Steven S. Kheloussi, PharmD, MBA, FAMCP Principal Consultant Kheloussi Consulting, LLC Click here for biography

	Christyn Edmundson, MD Director of Neuromuscular Medicine Swedish Neuroscience Institute Click here for biography

	Drake Reiter, PharmD Director, Pharmacy Operations Priority Health Click here for biography

Target Audience
The primary target audience for this initiative comprises medical directors, pharmacy directors, clinical pharmacists, specialty pharmacists, quality directors, and network physicians affiliated with various managed care organizations (MCOs), health systems, and other payer organizations. Other managed care professionals include nurses, case managers, policy administrators, utilization managers, C-suite executives, and IT professionals.

Statement of Need/Program Overview
Managed care professionals face unique challenges in optimizing outcomes for patients with MG, a rare, chronic autoimmune neuromuscular disorder characterized by fluctuating muscle weakness and fatigue. The increasing prevalence and complexity of MG, combined with rapid advances in targeted therapies, require updated knowledge and strategic approaches to coverage, management, and equitable access.

Educational Objectives
After completing this activity, participants should be able to demonstrate improved ability to:

Describe the clinical features and neuropathology of myasthenia gravis
Explain recommendations from current myasthenia gravis treatment guidelines
Review the myasthenia gravis treatment pipeline and new mechanisms of action that may provide benefits to patients, including safety, efficacy, ease of administration, and durability
Assess opportunities to improve patient wellbeing, caregiver burden, access to care, and health inequities for patients with myasthenia gravis

Accreditation Information

Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (Partners) and Impact Education, LLC. Partners is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Interprofessional Continuing Education (IPCE)
This activity was planned by and for the healthcare team, and learners will receive 0.75 Interprofessional Continuing Education (IPCE) credit for learning and change.

Physician Continuing Medical Education
Partners designates this live activity for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education
Partners designates this continuing education activity for 0.75 contact hours (0.075 CEUs) of the Accreditation Council for Pharmacy Education.

UAN: Coming Soon
Type of Activity: Knowledge

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.75 contact hour.

DISCLOSURE OF CONFLICTS OF INTEREST
Partners for Advancing Clinical Education (Partners) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial relationships they may have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to Partners policy. Partners is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

*Name of Faculty*	*Reported Financial Relationship*
Steven Kheloussi, PharmD, MBA, FAMCP	Nothing to disclose.
Christyn Edmundson, MD	Consultant/Advisor/Speaker: Amgen, Alnylam, Alexion, Argenx, Immunovant, Kyverna, UCB
Drake Reiter, PharmD	Nothing to disclose.

DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

FEE INFORMATION
There is no fee for this educational activity.